glp-1 nausea lawsuit in kentucky Lawyer Dangerous Drug Lawsuits - Kentucky
Description
doi: 10.1152/ajpendo.00233.2002
It would be important to reassess this pattern now with more widespread adoption of GLP-1s for obesity alone, since the study period ended in 2022
Biomarker Context and Metabolic Assessment Before Starting GLP-1 Beyond standard clinical criteria, baseline biomarker assessment helps PCPs predict GLP-1 responsiveness and tailor dosing strategies
Strathe A, Horn DB, Larsen MS, et al
Over a longerterm horizon, certain areas within medtech will continue to feel pressure from the rising prevalence of GLP1s, particularly as access, utilization, and cost reimbursement rates increase over time
Phenomixs CEO Mark Bagnall spoke with Pharmaceutical Executive about this data and what the impact is on GLP-1 users
